EQUILLIUM, INC. Operating Lease, Payments
EQUILLIUM, INC. (EQ) reported Operating Lease, Payments of $244.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-25
- EQUILLIUM, INC. operating lease, payments for the quarter ending 2025-12-31 was $39.00K, a 68.29% decline year-over-year.
- EQUILLIUM, INC. operating lease, payments for the quarter ending 2025-09-30 was $68.00K, a 38.18% decline year-over-year.
- EQUILLIUM, INC. operating lease, payments for the quarter ending 2025-06-30 was $41.00K, a 66.67% decline year-over-year.
- EQUILLIUM, INC. operating lease, payments for the quarter ending 2025-03-31 was $96.00K, a 21.31% decline year-over-year.
- EQUILLIUM, INC. operating lease, payments for fiscal 2025 was $244.00K, a 48.95% decline from fiscal 2024.
- EQUILLIUM, INC. operating lease, payments for fiscal 2024 was $478.00K, a 4.21% decline from fiscal 2023.
- EQUILLIUM, INC. operating lease, payments for fiscal 2023 was $499.00K, a 7.31% increase from fiscal 2022.
- EQUILLIUM, INC. operating lease, payments for fiscal 2022 was $465.00K, a 111.36% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $107.00K derived: sum of 2 quarters · filed 2026-03-25 | $148.00K derived: sum of 3 quarters · filed 2026-03-25 | $244.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $109.00K derived: sum of 2 quarters · filed 2025-11-13 | $205.00K 10-Q · filed 2025-11-13 | $328.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $137.00K 10-Q · filed 2025-08-14 | $260.00K derived: sum of 3 quarters · filed 2026-03-25 | $370.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | $96.00K 10-Q · filed 2025-05-14 | $219.00K derived: sum of 2 quarters · filed 2026-03-25 | $329.00K derived: sum of 3 quarters · filed 2026-03-25 | $452.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $233.00K derived: sum of 2 quarters · filed 2026-03-25 | $356.00K derived: sum of 3 quarters · filed 2026-03-25 | $478.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $233.00K derived: sum of 2 quarters · filed 2025-11-13 | $355.00K 10-Q · filed 2025-11-13 | $448.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $245.00K 10-Q · filed 2025-08-14 | $338.00K derived: sum of 3 quarters · filed 2025-08-14 | $484.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $122.00K 10-Q · filed 2025-05-14 | $215.00K derived: sum of 2 quarters · filed 2025-05-14 | $361.00K derived: sum of 3 quarters · filed 2025-05-14 | $454.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $239.00K derived: sum of 2 quarters · filed 2024-03-25 | $332.00K derived: sum of 3 quarters · filed 2024-03-25 | $499.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $239.00K derived: sum of 2 quarters · filed 2023-11-08 | $406.00K 10-Q · filed 2023-11-08 | $534.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $260.00K 10-Q · filed 2023-08-09 | $388.00K derived: sum of 3 quarters · filed 2023-08-09 | $542.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $167.00K 10-Q · filed 2023-05-11 | $295.00K derived: sum of 2 quarters · filed 2023-05-11 | $449.00K derived: sum of 3 quarters · filed 2023-05-11 | $553.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $282.00K derived: sum of 2 quarters · filed 2023-03-23 | $386.00K derived: sum of 3 quarters · filed 2023-03-23 | $465.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $258.00K derived: sum of 2 quarters · filed 2022-11-14 | $337.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $183.00K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $79.00K 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $220.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |